Cliff Asness's LLY Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 451,182 shares of Eli Lilly and Company (LLY) worth $330.82 M, representing 0.21% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in LLY, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2018, adding 1.59 M shares. Largest reduction occurred in Q3 2019, reducing 1.45 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Eli Lilly and Company (LLY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Eli Lilly and Company (LLY) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +2.8 M | Add 0.00% | 2.8 M | $49.32 |
| Q2 2013 | +3.88 M | Add 0.00% | 3.88 M | $49.12 |
| Q3 2013 | -564,803 | Reduce 14.56% | 3.31 M | $50.33 |
| Q4 2013 | +40,998 | Add 1.24% | 3.35 M | $51.00 |
| Q1 2014 | -1.14 M | Reduce 33.99% | 2.21 M | $58.86 |
| Q2 2014 | -295,500 | Reduce 13.34% | 1.92 M | $62.17 |
| Q3 2014 | -461,233 | Reduce 24.04% | 1.46 M | $64.85 |
| Q4 2014 | +610,321 | Add 41.87% | 2.07 M | $68.99 |
| Q1 2015 | +269,239 | Add 13.02% | 2.34 M | $72.65 |
| Q2 2015 | -349,718 | Reduce 14.96% | 1.99 M | $83.49 |
| Q3 2015 | +451,787 | Add 22.73% | 2.44 M | $83.69 |
| Q4 2015 | -78,844 | Reduce 3.23% | 2.36 M | $84.26 |
| Q1 2016 | -446,807 | Reduce 18.93% | 1.91 M | $72.01 |
| Q2 2016 | -580,360 | Reduce 30.33% | 1.33 M | $78.75 |
| Q3 2016 | +124,873 | Add 9.37% | 1.46 M | $80.26 |
| Q4 2016 | +30,655 | Add 2.10% | 1.49 M | $73.55 |
| Q1 2017 | -246,535 | Reduce 16.56% | 1.24 M | $84.11 |
| Q2 2017 | +365,539 | Add 29.42% | 1.61 M | $82.30 |
| Q3 2017 | +284,380 | Add 17.69% | 1.89 M | $85.54 |
| Q4 2017 | +158,755 | Add 8.39% | 2.05 M | $84.46 |
| Q1 2018 | -346,580 | Reduce 16.90% | 1.7 M | $77.37 |
| Q2 2018 | -637,563 | Reduce 37.41% | 1.07 M | $85.33 |
| Q3 2018 | +951,817 | Add 89.22% | 2.02 M | $107.31 |
| Q4 2018 | +1.59 M | Add 78.88% | 3.61 M | $115.72 |
| Q1 2019 | -782,294 | Reduce 21.66% | 2.83 M | $129.55 |
| Q2 2019 | +1.51 M | Add 53.28% | 4.34 M | $110.72 |
| Q3 2019 | -1.45 M | Reduce 33.37% | 2.89 M | $111.83 |
| Q4 2019 | -369,787 | Reduce 12.80% | 2.52 M | $130.78 |
| Q1 2020 | -1.05 M | Reduce 41.69% | 1.47 M | $135.23 |
| Q2 2020 | -131,280 | Reduce 8.94% | 1.34 M | $162.69 |
| Q3 2020 | +169,421 | Add 12.67% | 1.51 M | $145.68 |
| Q4 2020 | -66,733 | Reduce 4.43% | 1.44 M | $166.99 |
| Q1 2021 | -369,380 | Reduce 25.65% | 1.07 M | $185.38 |
| Q2 2021 | -117,454 | Reduce 10.97% | 953,360 | $229.52 |
| Q3 2021 | -53,712 | Reduce 5.63% | 899,648 | $231.05 |
| Q4 2021 | +77,648 | Add 8.63% | 977,296 | $276.22 |
| Q1 2022 | -107,175 | Reduce 10.97% | 870,121 | $286.37 |
| Q2 2022 | -331,785 | Reduce 38.13% | 538,336 | $323.10 |
| Q3 2022 | -55,251 | Reduce 10.26% | 483,085 | $323.35 |
| Q4 2022 | -106,760 | Reduce 22.10% | 376,325 | $365.84 |
| Q1 2023 | -45,133 | Reduce 11.99% | 331,192 | $343.11 |
| Q2 2023 | -27,007 | Reduce 8.15% | 304,185 | $466.71 |
| Q3 2023 | +1,448 | Add 0.48% | 305,633 | $537.13 |
| Q4 2023 | +30,302 | Add 9.91% | 335,935 | $582.92 |
| Q1 2024 | +68,495 | Add 20.39% | 404,430 | $777.96 |
| Q2 2024 | +70,122 | Add 17.34% | 474,552 | $905.38 |
| Q3 2024 | +203,085 | Add 42.80% | 677,637 | $873.31 |
| Q4 2024 | -33,693 | Reduce 4.97% | 643,944 | $770.51 |
| Q1 2025 | -76,441 | Reduce 11.87% | 567,503 | $803.79 |
| Q2 2025 | -220,528 | Reduce 38.86% | 346,975 | $777.14 |
| Q3 2025 | +104,207 | Add 30.03% | 451,182 | $733.24 |
Cliff Asness's Eli Lilly and Company Investment FAQs
Cliff Asness first purchased Eli Lilly and Company (LLY) in Q4 2012, acquiring 2,802,050 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Eli Lilly and Company (LLY) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Eli Lilly and Company (LLY) was in Q2 2013, adding 3,878,291 shares worth $190.5 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 451,182 shares of Eli Lilly and Company (LLY), valued at approximately $330.82 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Eli Lilly and Company (LLY) represents approximately 0.21% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Eli Lilly and Company (LLY) was 4,335,702 shares, as reported at the end of Q2 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.